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Abstract Bodyweight has been shown to influence
anidulafungin exposure, but data from obese patients are
lacking. We determined anidulafungin pharmacokinetics
(100-mg single dose) in eight morbidly obese subjects
(body mass index [40 kg/m2). Anidulafungin exposure
was on average 32.5 % lower compared with the general
patient population, suggesting dose increases may be
required in this population.
Key Points
Anidulafungin exposure was on average 32.5 %
lower compared with the general patient population.
To normalize the exposure to population values,
increasing the anidulafungin maintenance dose by
50 % (i.e., 150 mg) could be considered.
To achieve adequate exposure at the beginning of
therapy, increasing the loading dose by 50 % (i.e.,
300 mg) could be considered.
1 Introduction
The global prevalence of overweight and obesity has
increased at an alarming rate during the previous few
decades. If recent trends continue, nearly 58 % of the
world’s adult population will be overweight or obese in
2030 [1]. Obesity increases the risk of a wide array of co-
morbidities and is an established risk factor for nosocomial
infections. Because obese patients are subject to a variety
of (patho)physiological changes compared with non-obese
patients, the pharmacokinetic (PK) and/or pharmacody-
namic profile of antimicrobials might be altered [2].
Anidulafungin is an echinocandin antifungal agent
approved for the intravenous treatment of invasive can-
didiasis and candidemia [3]. At standard doses (200-mg
loading dose, 100-mg maintenance dose), anidulafungin
displays linear PK, with a volume of distribution close to
total body water (0.6 L/kg), a clearance of about 1 L/h, and
an elimination half-life of approximately 24 h [3, 4].
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The PK of anidulafungin has been well described in
healthy subjects and several patient populations [4–10],
although the weight range in these studies was small.
Weight has been reported to be an influential factor on
anidulafungin exposure [4, 8–10]. This may therefore result
in suboptimal exposure of anidulafungin in obese patients,
possibly requiring a different dosing strategy in this pop-
ulation. In this study, we aim to describe the PK of
anidulafungin in morbidly obese subjects with body mass
index (BMI)[40 kg/m2.
2 Materials and Methods
2.1 Study Design and Subjects
This open-label phase IV study (ClinicalTrials.gov Identi-
fier: NCT02021123) was approved by the Ethics Com-
mittee of the Radboud University Medical Center in 2014
and conducted in accordance with the declaration of Hel-
sinki. Before inclusion, all subjects gave written informed
consent.
From August until October 2014, adult morbidly obese
subjects (BMI [40 kg/m2; with no fungal infection)
undergoing laparoscopic gastric bypass or sleeve surgery
were eligible for inclusion. Subjects were excluded in the
case of hypersensitivity to echinocandins and/or abuse of
alcohol or drugs for the previous 3 months.
2.2 Study Procedure
Upon inclusion, patient demographics, clinical character-
istics, and concomitant medications were reported. Sub-
jects received a single intravenous 100-mg dose of
anidulafungin before laparoscopic bariatric surgery. The
anidulafungin infusion was administered 2.5 h before
induction of anesthesia with an infusion rate of 1.1 mg/min
[3]. There were no restrictions in the protocol with regard
to concomitant medication.
A PK curve was drawn at predefined times of T = 0.5,
1, 1.5 (end of infusion), 2, 4, 6, 8, 10, 12, 24, and 48 h post-
infusion (n = 11). Blood samples were collected in
lithium-heparin-containing tubes (non-gel) and centrifuged
at 19009g (3000 rpm) for 5 min at 4 C within 30 min of
collection. Plasma was immediately stored at -80 C.
Anidulafungin samples were measured by ultra-perfor-
mance liquid with fluorescence detection [8].
2.3 Analytical Assay
Anidulafungin samples were measured by ultra-perfor-
mance liquid chromatography with fluorescence detection
(dynamic range for anidulafungin in plasma:
0.008–8.43 mg/L with a concentration-dependent accuracy
range [n = 15] of 94.2–103.5 %). A seven-point calibration
curve with three quality-control samples was used. Intraday
precision ranged between 0.87 and 1.84 % (n = 5) and
interday precision varied between 0.53 and 1.58 % (n = 15).
Anidulafungin recovery was 93 %. Stability of anidula-
fungin remained unchanged by three freeze–thaw cycles.
2.4 Safety
Blood samples for the purpose of laboratory safety were
collected at T = 0, 24, and 48 h for the determination of
biochemical and hematological parameters (sodium,
potassium, chloride, calcium, phosphate albumin, blood
urea nitrogen, aspartate aminotransaminase, alanine
aminotransferase, gamma-glutamyltransferase, alkaline
phosphatase, bilirubin (total), lactate dehydrogenase,
C-reactive protein, triglycerides, creatinine kinase, crea-
tinine, uric acid, hemoglobin, hematocrit, white blood cells
differential, platelets, and red blood cell count).
Adverse events (AEs) were reported regardless of
potential relationship to anidulafungin (including adverse
drug reactions, illness that developed during the study,
exacerbations of pre-existing illness, or abnormal labora-
tory values requiring intervention or diagnostic evaluation)
until discharge.
There were no restrictions in the protocol with regard to
concomitant medication.
2.5 Anidulafungin PK Data Analysis
PK parameters were calculated using non-compartmental
analysis (Phoenix WinNonlin 6.3; Pharsight Corp, Moun-
tain View, CA, USA). The area under the plasma con-
centration–time curve from 0 to time of last sample
(AUC0–48) was calculated using the linear up-log down
trapezoidal rule. The AUC from 0 to infinity (AUC0–inf)
was determined as follows:
AUC0inf ¼ AUC048 þ last observed concentration=ke:
Anidulafungin exposure in this cohort of morbidly obese
subjects was compared with the exposure in the general
patient population [10], given that AUC0–inf (single
dose) = AUC0–24 (steady state).
Maximum plasma concentration was directly observed
from the data. Total body clearance was calculated as D/
AUC0–inf and volume of distribution (VD) was calculated as
D/AUC0–inf 9 ke. Half-life was calculated by ln(2)/ke.
Elimination rate constant (ke) was estimated by log-linear
regression of the terminal portions (minimum of four
points, user defined) of the plasma concentration-vs.-time
curves.
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2.6 Statistical Analysis
Descriptive statistics (e.g., geometric mean, range, inter-
patient variability [calculated as geometric coefficient of
variation]) were calculated for anidulafungin PK parame-
ters. A Spearman’s correlation was run to assess the cor-
relation between AUC and weight in SPSS 20.0 (SPSS
Inc., Chicago, IL, USA). A p value of\0.05 was consid-
ered statistically significant. Using a power calculation
(alpha = 0.05, power = 0.8) based on the exposure and
standard deviation in the general patient population [9, 10]
and the assumption of a mean AUC0–inf of 75 mg 9 h/L in
the target obese population, this would require eight
patients.
3 Results
3.1 Subjects
Eight subjects (three male, five female; all Caucasian) were
included. Median (range) age was 43 years (29–66 years).
Geometric mean (range) weight, BMI, lean body mass
(calculated according to Janmahasatian et al. [11], and
body surface area and waist/hip ratio were 144.7 kg
(124.1–166.5), 48.9 kg/m2 (39.9–57.6), 72.4 kg
(58.3–91.0), 2.49 m2 (2.20–2.78), and 0.93 (0.85–1.11),
respectively (Table 1). Individual and average plasma
concentration–time curves of anidulafungin are shown in
Fig. 1.
3.2 Anidulafungin PK
Geometric mean (range) PK parameters were: AUC0–inf
72.9 mg 9 h/L (46.3–100.1), AUC0–48 54.1 mg 9 h/L
(35.0–68.9), maximum plasma concentration 3.2 mg/L
(2.6–4.1), volume of distribution 46.9 L (39.6–56.7),
clearance 1.4 L/h (1.0–2.2), half-life 23.7 h (17.0–29.8),
and ke 0.029 1/h (0.023–0.041), see Table 1. In total,
35.1 % of the AUC0–48 was extrapolated to AUC0–inf.
Limited inter-individual variability was seen with AUC0–inf
(coefficient of variation (CV) of 20.7 %; calculated on the
arithmetic mean). No concurrent medications known to
significantly influence anidulafungin PK were administered
[3].
A strong non-significant negative correlation between
anidulafungin AUC0–inf and absolute bodyweight or
anidulafungin AUC0–inf and body surface area was found:
rs(8) = -0.6429, p = 0.096 and rs(8) = - 0.7066,
p = 0.058, respectively. Other parameters such as lean
body mass resulted in poorer correlations. For the purpose
of comparison with other studies, we also calculated the
arithmetic mean AUC. The mean AUC0–inf (74.4 mg 9 h/
L, CV 20.7 %); range 46.3–100.1) following a single dose
in our patient population was on average 32.5 % lower
compared with the mean AUC0–24 at steady state in the
general patient population (110.3 mg 9 h/L, CV 32.5 %)
[10]. With this, the AUC0–inf in this cohort of morbidly
obese patients is at the lower end of the exposure distri-
bution of the general patient population.
3.3 Safety
No serious AEs were reported. All single-dose infusions
were well tolerated. Subjects experienced 48 new or
aggravated AEs during follow-up (laboratory safety until
48 h and clinical AEs until discharge), of which 16
(33.3 %) were possibly related to anidulafungin. These
AEs are most likely related to the surgical procedure (e.g.,
increase in aspartate aminotransferase, alanine amino-
transferase, creatinine kinase, nausea, headache) but a
relation with anidulafungin infusion could not be excluded.
All AEs were mild, transient, and resolved spontaneously.
4 Discussion
To our knowledge, this is the first clinical study investi-
gating the influence of extreme bodyweight (BMI[ 40 kg/
m2) on anidulafungin PK. The findings from this study
show that this cohort of morbidly obese subjects has a
lower exposure compared with the exposure in non-obese
individuals as described in the literature [5, 10]. The inter-
individual variability of anidulafungin in this population is
comparable to healthy non-obese volunteers [7].
Previously, it has been suggested that increased body
size results in lower anidulafungin exposure, as weight was
identified as a covariate affecting anidulafungin clearance
[4, 9, 10] and central volume of distribution [4, 8].
Although the weight range was limited in those studies
(only seven patients were[120 kg), it was predicted that
anidulafungin exposure could be 30 % lower in a typical
150-kg male patient compared with a typical 60-kg male
patient [10]. In the study of Liu et al., a patient weighing
240 kg was included, in whom a dose increase to
150 mg/day resulted in exposure comparable to other
critically ill patients, albeit at the lower end of the AUC
range (AUC0–24 92.7 vs. 55.3 mg 9 h/L; 37 mg 9 h/L if
extrapolated to 100 mg) [7]. The above findings of
decreasing exposure as a function of weight were also
observed with the other echinocandins, caspofungin and
micafungin [12, 13].
We show that none of the morbidly obese patients
included in our study obtain the AUC of the general patient
population at standard doses of anidulafungin (Table 1),
thereby possibly introducing the risk of therapeutic failure.
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No specific clinical target AUC value for anidulafungin is
established. In addition, it must be noted that a successful
clinical response was observed in patients with invasive
candidiasis (including candidemia) and low exposure in
another study [10]. Our hypothesis is that a favorable
response is likely associated with an infection with very
susceptible species. Nevertheless, morbidly obese patients
infected with pathogens with reduced susceptibility are still
at risk for therapeutic failure. Considering the fact that
anidulafungin is well tolerated in doses up to 300 mg [8],
and pathogen susceptibility at the start of therapy is often
unknown, we propose an approach to adapt the empiric
dose to achieve the general population average exposure
(AUC0–24 110 mg 9 h/L) in this cohort of patients
(BMI[ 40 kg/m2) [10]. To normalize the exposure to
population values, increasing the anidulafungin mainte-
nance dose to 150 mg (?50 %) would proportionally
increase the AUC0–24 to nearly 110 mg 9 h/L (based on
linear kinetics) [3]. In parallel, increasing the loading dose
by 50 % (i.e., 300 mg) could be considered to achieve
adequate exposure at the beginning of therapy [5, 10].
A different approach would be to increase the dose
based on clinical failure or by using therapeutic drug
monitoring (individualized drug dosing based on the
measurement and interpretation of drug concentrations
taking into account pathogen susceptibility). The first
option will likely save drug costs. The latter approach is a
more personalized schedule that can be deployed in
patients with a high a priori risk of low exposure such as
the intensive care unit population [10]. Being obese may
have an additive effect on exposure. In other words, the
exposure in critically ill, morbidly obese patients with
candidemia/invasive candidiasis may be even more pro-
nounced compared with an intensive care unit population
or obesity alone. The use of therapeutic drug monitoring in
such a clinical situation deserves further study.
Our study is conducted with a relatively small sample
size, without a non-obese control group. Ideally, anidula-
fungin PK in this cohort of morbidly obese patients is
directly compared with PK in non-obese individuals also
receiving a single 100-mg dose. We did not have a control
group in our study design as this study was established for
exploratory purposes. Instead, we calculated AUC0–inf after
a single dose of 100 mg anidulafungin, which would allow
for comparisons with AUC0–24 at steady state in the liter-
ature (next to a comparison with single-dose studies).
Because of the relatively long half-life of anidulafungin of
23.7 h (Table 1), more than 20 % of the AUC0–48 was
extrapolated to AUC0–inf (35.1 %), which may bias this
estimation of AUC0–inf. We expect this bias to be minimal.
Ideally, sampling up until 72 h would have been done to
better estimate AUC0–inf. In our situation, patients were
discharged after 48 h, so this was the compromise between
patient burden and PK results. A strong negative but non-
significant correlation between body weight and AUC as
well as body surface area and AUC was found. We want to
highlight that these results should be interpreted with
caution as there is only eight people in the analysis and the
relation is not significant. Therefore, these results should be
regarded as explorative for anidulafungin PK in obese
subjects.
5 Conclusion
The lower anidulafungin exposure in our ‘healthy’ mor-
bidly obese subjects compared with literature values in
non-obese patients suggests that anidulafungin dosing
could be optimized in (extreme) morbidly obese patients
with fungemia. As a priori dosing information regarding
the appropriate dose of anidulafungin for heavy patients is
lacking, the results of the current study show that increases
of both the loading dose and maintenance dose should be
considered in patients with a BMI[40 kg/m2. We propose
a 50 % increased loading and maintenance dose for mor-
bidly obese patients.
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